Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
US students studying housing, health outcomes and sustainability win 2026 Rhodes scholarships - 2Which Breakfast Enraptures Your Taste Buds? Vote
- 3Unwinding History's Secrets: Looking for the Response to Antiquated Human advancements
- 4New study measures titanium in Apollo rock to uncover Moon’s early chemistry
- 5Top German court to rule on claims by Wirecard shareholders
- The many ways that baking is winter therapy. With a delicious ending
- 5 Advancement Developments in Biotechnology
- Dozens injured in Russia after train crashes, overturns
- the Wild in Style: The Reduced Portage Mustang's Bold Heritage
- Miss 'Stranger Things' already? Here's how you can get your Upside Down fix in 2026 with spinoffs, games and more
- 6 Tire Brands Reasonable for Seniors
- EU states agree first step for Ukraine reparations fund
- The Delight of Perusing: Book Proposals for Each Class
- Two Endangered Bengal Tiger Cubs Die Days Apart at Zoo After Contracting Virus
